Abstract
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.
MeSH terms
-
Adult
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / immunology
-
Arthritis, Juvenile / complications*
-
Arthritis, Juvenile / drug therapy
-
Disease-Free Survival
-
Etanercept
-
Female
-
Humans
-
Immunocompromised Host
-
Immunoglobulin G / adverse effects*
-
Immunoglobulin G / immunology
-
Lupus Nephritis / chemically induced*
-
Lupus Nephritis / immunology
-
Lupus Nephritis / pathology
-
Receptors, Tumor Necrosis Factor / immunology
-
Recombinant Fusion Proteins / adverse effects*
-
Recombinant Fusion Proteins / immunology
-
Vasculitis, Leukocytoclastic, Cutaneous / chemically induced*
-
Vasculitis, Leukocytoclastic, Cutaneous / immunology
-
Vasculitis, Leukocytoclastic, Cutaneous / pathology
-
Withholding Treatment
Substances
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Recombinant Fusion Proteins
-
Etanercept